Bio-Techne Corp (NASDAQ: TECH)’s stock price has decreased by -4.07 compared to its previous closing price of 78.71. However, the company has seen a 0.51% increase in its stock price over the last five trading sessions. zacks.com reported 2025-01-21 that Investors interested in Medical – Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and Techne (TECH). But which of these two companies is the best option for those looking for undervalued stocks?
Is It Worth Investing in Bio-Techne Corp (NASDAQ: TECH) Right Now?
The price-to-earnings ratio for Bio-Techne Corp (NASDAQ: TECH) is 80.48x, which is above its average ratio. Moreover, the 36-month beta value for TECH is 1.27. Analysts have varying opinions on the stock, with 9 analysts rating it as a “buy,” 3 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for TECH is 157.11M and currently, short sellers hold a 2.40% of that float. On January 23, 2025, TECH’s average trading volume was 915.91K shares.
TECH’s Market Performance
TECH’s stock has seen a 0.51% increase for the week, with a 5.77% rise in the past month and a 7.32% gain in the past quarter. The volatility ratio for the week is 3.16%, and the volatility levels for the past 30 days are at 3.15% for Bio-Techne Corp The simple moving average for the past 20 days is 1.34% for TECH’s stock, with a 1.63% simple moving average for the past 200 days.
Analysts’ Opinion of TECH
Many brokerage firms have already submitted their reports for TECH stocks, with Citigroup repeating the rating for TECH by listing it as a “Neutral.” The predicted price for TECH in the upcoming period, according to Citigroup is $85 based on the research report published on May 22, 2024 of the previous year 2024.
Scotiabank, on the other hand, stated in their research note that they expect to see TECH reach a price target of $80. The rating they have provided for TECH stocks is “Sector Outperform” according to the report published on February 08th, 2024.
Stifel gave a rating of “Hold” to TECH, setting the target price at $65 in the report published on February 02nd of the previous year.
TECH Trading at 1.98% from the 50-Day Moving Average
After a stumble in the market that brought TECH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -11.76% of loss for the given period.
Volatility was left at 3.15%, however, over the last 30 days, the volatility rate increased by 3.16%, as shares surge +2.70% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -1.67% lower at present.
During the last 5 trading sessions, TECH rose by +0.02%, which changed the moving average for the period of 200-days by +12.17% in comparison to the 20-day moving average, which settled at $74.49. In addition, Bio-Techne Corp saw 4.83% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TECH starting from BAUMGARTNER ROBERT V, who sale 16,000 shares at the price of $72.10 back on Aug 08 ’24. After this action, BAUMGARTNER ROBERT V now owns 43,401 shares of Bio-Techne Corp, valued at $1,153,664 using the latest closing price.
ROBERT V. BAUMGARTNER, the Director of Bio-Techne Corp, proposed sale 16,000 shares at $72.10 during a trade that took place back on Aug 08 ’24, which means that ROBERT V. BAUMGARTNER is holding shares at $1,153,664 based on the most recent closing price.
Stock Fundamentals for TECH
Current profitability levels for the company are sitting at:
- 0.2 for the present operating margin
- 0.66 for the gross margin
The net margin for Bio-Techne Corp stands at 0.13. The total capital return value is set at 0.09. Equity return is now at value 7.29, with 5.49 for asset returns.
Based on Bio-Techne Corp (TECH), the company’s capital structure generated 0.16 points at debt to capital in total, while cash flow to debt ratio is standing at 0.76. The debt to equity ratio resting at 0.19. The interest coverage ratio of the stock is 17.59.
Currently, EBITDA for the company is 310.37 million with net debt to EBITDA at 0.61. When we switch over and look at the enterprise to sales, we see a ratio of 10.39. The receivables turnover for the company is 5.24for trailing twelve months and the total asset turnover is 0.43. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.56.
Conclusion
To wrap up, the performance of Bio-Techne Corp (TECH) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
